These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 31134088)

  • 1. Interleukin-35 Dampens CD8
    Yang L; Shao X; Jia S; Zhang Q; Jin Z
    Front Immunol; 2019; 10():1032. PubMed ID: 31134088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-35 Suppresses CD8
    Yang L; Zhang Q; Song J; Wang W; Jin Z
    Dig Dis Sci; 2020 Dec; 65(12):3614-3623. PubMed ID: 31974915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-7 enhances anti-tumor activity of CD8
    Teng D; Ding L; Cai B; Luo Q; Wang H
    Cytokine; 2019 Jun; 118():115-123. PubMed ID: 29655570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma.
    Liu S; Yang L; Jia S; Zhao R; Jin Z
    Int Immunopharmacol; 2021 Nov; 100():108161. PubMed ID: 34555643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-35 Suppresses Interleukin-9-Secreting CD4
    Zhang Q; Yang L; Liu S; Zhang M; Jin Z
    Front Immunol; 2021; 12():645835. PubMed ID: 34177894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
    Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z
    Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-37 suppresses the cytotoxicity of hepatitis B virus peptides-induced CD8+ T cells in patients with acute hepatitis B.
    Liu Q; Zhou Q; Wang M; Pang B
    Biomol Biomed; 2023 May; 23(3):527-534. PubMed ID: 36326182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-35 has a Protective Role in Infectious Mononucleosis-Induced Liver Inflammation Probably by Inhibiting CD8
    Gao Y; Li L; Hu X; Zhang W; Li Y
    Arch Immunol Ther Exp (Warsz); 2022 Oct; 70(1):25. PubMed ID: 36219249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch signaling pathway suppresses CD8
    Li S; Wang Z; Li XJ
    Int Immunopharmacol; 2018 Oct; 63():129-136. PubMed ID: 30086535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-7 augments CD8
    Hou H; Kang Y; Zeng Y; Li Y; Shang J
    Cytokine; 2018 Feb; 102():26-33. PubMed ID: 29275010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.
    Liu X; Ren H; Guo H; Wang W; Zhao N
    Clin Exp Immunol; 2021 Feb; 203(2):219-229. PubMed ID: 33030251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients.
    Kuang DM; Peng C; Zhao Q; Wu Y; Zhu LY; Wang J; Yin XY; Li L; Zheng L
    J Immunol; 2010 Aug; 185(3):1544-9. PubMed ID: 20581151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients.
    Zhao Q; Xiao X; Wu Y; Wei Y; Zhu LY; Zhou J; Kuang DM
    Eur J Immunol; 2011 Aug; 41(8):2314-22. PubMed ID: 21674477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant expression of p-STAT3 in peripheral blood CD4+ and CD8+ T cells related to hepatocellular carcinoma development.
    Wang X; Xin W; Zhang H; Zhang F; Gao M; Yuan L; Xu X; Hu X; Zhao M
    Mol Med Rep; 2014 Nov; 10(5):2649-56. PubMed ID: 25175640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γδ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways.
    Jiang H; Yang Z; Song Z; Green M; Song H; Shao Q
    Int Immunopharmacol; 2019 May; 70():167-173. PubMed ID: 30802679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-35 suppresses antitumor activity of circulating CD8
    Liu MX; Liu QY; Liu Y; Cheng ZM; Liu L; Zhang L; Sun DH
    Connect Tissue Res; 2019 Jul; 60(4):367-375. PubMed ID: 30616389
    [No Abstract]   [Full Text] [Related]  

  • 18. Interleukin-7 promotes CD8
    Tian X; Su Z; Guo S; Wang C; Zhang X; Du J
    Int Immunopharmacol; 2019 Oct; 75():105773. PubMed ID: 31349155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
    Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
    Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.